During the previous segment of this blog series, cell collection experts at HemaCare reviewed apheresis best practices in donor recruitment, apheresis technology, and cell handling techniques. This week, we define the difference between purity and yield, and examine their contribution to starting material quality.
Welcome to the 2nd segment of our blog series on what impacts cell therapy starting material quality. This week, we examine what comprises apheresis best practices, which are critical to the quality of apheresis materials.
This week we begin a 3-part blog series on the intricacies of optimizing the quality of cell therapy starting materials. Cell and gene therapies have the potential to transform healthcare. Successfully bringing these therapies to the market, however, is a challenge. The intrinsic variability of living cells carries an increased risk and cost to therapeutic development not encountered with traditional medicine. Those risks are being countered with innovative strategies and technologies that experts hope will bridge the translational gap between research and industry.
The mobilization of hematopoietic stem and progenitor cells (HSPC) to the peripheral blood is an essential process enabling the collection of these cells from an easily accessible source. The use of peripheral blood as a source of stem cells has significantly improved donor safety, since it does not require a surgical procedure for cell collection, and it is associated with a significantly accelerated reconstitution of the immune system in transplant patients.
The human induced pluripotent stem cell (iPSC) research landscape is rapidly evolving. We recently discussed the current trend in stem cell research to streamline the production of induced pluripotent stem cells (iPSC) from peripheral blood mononuclear cells (PBMCs). Recent exciting studies have indicated that harnessing iPSCs self-renewal ability to manufacture cell therapies is now becoming a reality. Just 4 years ago, the pharmaceutical company Takeda and The Center for iPS Cell Research and Application (CiRA) at Kyoto University entered a 10-year joint research collaboration. A few weeks ago, it was announced that Takeda has advanced the first product from its collaboration with CiRA - a highly scalable off-the-shelf CAR-T cell therapy to treat cancer - into pre-clinical development. Here, we briefly discuss the iCART science behind the Takeda study and its potential implications for an “off-the-shelf” CAR-T cell therapy.